Author Archive

Abbott Gets Tough with Thailand

In response to Thailand’s decision to issue compulsory licenses for Kaletra and for Plavix, effectively bypassing their patents by purchasing generic versions from India, Abbott has responded by redusing to launch any new drugs in Thailand. As I discussed in an earlier post, price controls and compulsory licensing give buyers more power … for a […]

Carnival of Biotechnology

Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report that tens of thousands of pharma sales reps are suing current and former employers for overtime – $1 billion in settlements could be at stake. H.S. Ayoub presents The Biotech Industry: 30 Years of Failure […]

Write a chapter for my book on Advanced Topics in Biotechnology Business Development

Following up on the success of “Building Biotechnology” (, I’m in the late stages of assembling a more advanced follow-up book featuring articles from industry insiders with deep experience. Join a dozen other industry insiders writing about topics in: – Business Planning – Funding – Valuation – Intellectual Property – Licensing and technology transfer – […]

Drug Patent Expirations in April 2007

Courtesy of Drug Patent Expirations in April 2007*Drugs may be covered by more than one patent Tradename Applicant Generic Name Patent Number Patent Expiration AMBIEN Sanofi Aventis Us zolpidem tartrate 4,382,938 APR 21,2007 AMBIEN CR Sanofi Aventis Us zolpidem tartrate 4,382,938 APR 21,2007 BIDIL Nitromed hydralazine hydrochloride; isosorbide dinitrate 4,868,179 APR 22,2007 DEPAKOTE ER […]

Genentech goes offshore

Genentech is investing $140mm in a new biologic manufacturing plant in Singapore. The first commercial-scale microbial fermentation plant in Singapore, and a significant International investment by US-based Genentech. This is the latest of a number of international manufacturing and R&D centers being located in Singapore, and is a sign of the growing trend of biotechnology […]

Xenotourism: Scary Stuff

Just came across an article on diabetics going to Mexico to receive pig xenotransplants. Unlike other forms of medical tourism, where patients travel to other countries for lower cost treatments, better quality treatments, or to receive ethically questionable organ transplants, xenotransplantation carries significant safety concerns. Xenotransplantation is the transplantation of organs or tissues from non-humans […]

The commercial prospects of biogenerics – how much will they save?

This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the status of biogenerics, background on the key issues, and the impacts on the industry of the various possible approval schemes. Clinical Trials The clinical trial requirement for biogenerics is the leading issue from a regulatory […]